Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
2017 · Science · 4,526 citations
https://doi.org/10.1126/science.aan4236
I
Isabella C. Glitza
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
316
Papers
14.2K
Citations
38
h-index
61
i10-index
Isabella C. Glitza is an academic researcher from Roswell Park Comprehensive Cancer Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Immune cells in cancer. The author has an h-index of 38, co-authored 269 publications.
Papers by this author
worksNeoadjuvant relatlimab and nivolumab in resectable melanoma
2022 · Nature · 317 citations
https://doi.org/10.1038/s41586-022-05368-8
Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐<scp>PD</scp>‐1 antibody therapy: a report on bullous skin eruptions
2016 · Journal of Cutaneous Pathology · 130 citations
https://doi.org/10.1111/cup.12717
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
2018 · ESMO Open · 66 citations
https://doi.org/10.1136/esmoopen-2017-000283
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma
2020 · Clinical Cancer Research · 64 citations
https://doi.org/10.1158/1078-0432.ccr-19-2670
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions
2018 · Journal of Cutaneous Pathology · 47 citations
https://doi.org/10.1111/cup.13312
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat